Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance by Johnathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi

Get full text